|
| 地西他滨联合IAG/DAG治疗急性髓系白血病的临床疗效 |
| Therapeutic effect of decitabine combined with reduced IAG/DAG on acute myeloid leukemia |
| 投稿时间：2020-01-07 |
| DOI：10.3969/j.issn.1000-0399.2020.05.006 |
| 中文关键词: 地西他滨 伊达比星 柔红霉素 急性髓系白血病 |
| 英文关键词: Decitabine Idarubicin Daunorubicin Acute myeloid leukemia |
| 基金项目:安徽省高校自然科学研究项目（项目编号：KJ2017A834） |
|
| 摘要点击次数: 1196 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨地西他滨（DAC）联合IAG/DAG治疗急性髓系白血病（AML）的临床疗效与安全性。方法 选取2017年6月至2019年12月安徽医科大学第一附属医院血液科收治的23例初治或复发AML患者，采用DAC联合IAG/DAG诱导治疗，统计分析临床疗效及安全性。结果 23例患者均予以DAC联合IAG/DAG诱导化疗，其中完全缓解13例，部分缓解2例，总有效率为65.22%。23例患者均出现Ⅲ～Ⅳ级的粒细胞和血小板减少，1例患者因严重脑出血死亡。结论 DAC联合IAG/DAG治疗AML临床疗效较好，且不良反应可耐受，安全性高，值得临床推广应用。 |
| 英文摘要: |
| Objective To observe the clinical efficacy and safety of decitabine combined with IAG/DAG in the treatment of acute myeloid leukemia(AML). Methods Twenty-three patients with AML admitted from June 2017 to December 2019 were treated with decitabine combined with IAG/DAG. The clinical efficacy and safety were evaluated. Results All 23 patients received decitabine combined with IAG/DAG induction chemotherapy.Among them,13 patients achieved complete remission,2 patients achieved partial remission, and the overall response rate was 65.22%.All patients had grade III~IV neutropenia and thrombocytopenia, and one patient died of severe cerebral hemorrhage. Non-hematologic toxicity such as gastrointestinal reactions, liver function damage and infection were controllable. Conclusions Decitabine combined with IAG/DAG for AML has good clinical efficacy, tolerable adverse reactions, and high safety, thus it is worth clinical promotion and application for poor physical performance patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
